BIOCELTIX S.A. ZY -10 Market Cap ($89.73 Million)
Market Cap & Net Worth: BIOCELTIX S.A. ZY -10 (XI3)
BIOCELTIX S.A. ZY -10 market cap. BIOCELTIX S.A. ZY -10 (F:XI3) has a market capitalization of $89.73 Million (€76.75 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #19434 globally and #1788 in its home market, demonstrating a 10.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOCELTIX S.A. ZY -10's stock price €20.40 by its total outstanding shares 5532253 (5.53 Million). Also see BIOCELTIX S.A. ZY -10 cash conversion from operations for how efficiently the company converts equity into cash flow.
BIOCELTIX S.A. ZY -10 Market Cap History (2021–2026)
BIOCELTIX S.A. ZY -10 market cap history from 2021 to 2026. Data shows growth from $71.15 Million to $131.94 Million (23.85% CAGR). Check latest BIOCELTIX S.A. ZY -10 stock price today for real-time trading data and today's change.
BIOCELTIX S.A. ZY -10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOCELTIX S.A. ZY -10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore XI3 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of XI3 by Market Capitalization
Companies near BIOCELTIX S.A. ZY -10 in the global market cap rankings as of November 4, 2026. Also see balance sheet size of BIOCELTIX S.A. ZY -10 for a full breakdown of the balance sheet.
Key companies related to BIOCELTIX S.A. ZY -10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of BIOCELTIX S.A. ZY -10 (2021–2026)
Market capitalization of BIOCELTIX S.A. ZY -10 from 2021 to today. Between 2021 and today, BIOCELTIX S.A. ZY -10's market cap moved from $71.15 Million to $ 131.94 Million, with a yearly change of 23.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €131.94 Million | -16.22% |
| 2025 | €157.49 Million | +36.49% |
| 2024 | €115.39 Million | -8.51% |
| 2023 | €126.12 Million | +141.34% |
| 2022 | €52.26 Million | -26.55% |
| 2021 | €71.15 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of BIOCELTIX S.A. ZY -10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $89.73 Million USD |
| MoneyControl | $89.73 Million USD |
| MarketWatch | $89.73 Million USD |
| marketcap.company | $89.73 Million USD |
| Reuters | $89.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more